Kemwell provides extensive mammalian cell culture-based formulation development services. The labs have the capability of performing complete process development, process optimization, scale-up, technology-transfers and process characterization.
Integrity Bio is a protein formulation development, fill finish, and drug delivery CMO. Injectable formulations include protein,antibody, vaccine, and peptide. http://www.integritybio.com
High-throughput Miniaturized Bioreactors for Cell Culture Process Developmen...KBI Biopharma
Decreasing the timeframe for cell culture process development has been a key goal towards accelerating biopharmaceutical development. Automated Micro-scale Bioreactors (ambrTM) is an advanced micro bioreactor system with miniature single-use bioreactors with a 9-15mL working volume controlled by an automated workstation. This system was compared to conventional bioreactor systems in terms of its performance for the production of a monoclonal antibody and a non-antibody molecule in recombinant Chinese Hamster Ovary (CHO) cell lines.
The miniaturized bioreactor system was found to produce cell culture profiles that matched across scales to 3L, 15L and 200L stirred tank bioreactors. Moreover, changes to important process parameters in ambrTM resulted in predictable cell growth, viability and titer changes, which were in good agreement to historical data from the larger scales. ambrTM was found to successfully reproduce variations in temperature, dissolved oxygen and pH conditions similar to the larger bioreactor systems. Additionally, the miniature bioreactors were found to react well to perturbations in pH and dissolved oxygen through adjustments to the PID control loop. Overall, the studies demonstrate the utility of the ambrTM system as a high throughput system for cell culture process development.
Speed to GMP: Moving from Rapid Process Development to High Throughput Tech T...KBI Biopharma
This document discusses strategies for rapidly transferring biologics manufacturing processes from development to commercial production. It provides examples of how KBI Biopharma employs standardized platform processes and integrated development approaches to minimize changes between scales. For antibody processes, extensive use of platform cell lines, media, and unit operations allows seamless transfer. Non-antibody processes require more customization but subsequent products can still leverage a base platform. Tech transfer timelines are established early and deliverables like batch records are reviewed. This enables timely preparation for cGMP manufacturing and regulatory filings.
Presentation at BPI West by Abhinav A. Shukla, Ph.D. Senior Vice President Development & Manufacturing KBI Biopharma, Durham NC, February 27 – March 2, 2017, Platforms for mAb Commercialization
Quality by Design at a Biopharma CMO (Contract Manufacturing Organization)KBI Biopharma
A presentation by Abhinav A. Shukla, Ph.D., KBI's Vice President of Process Development & Manufacturing delivered at the ACC/QbD Conference (Society for Biological Engineering, AIChE), Coronado Island, CA, 2013.
Mycenax is a CDMO located in Taiwan that provides services for biologics development from cell line development through fill/finish. They have expertise in mammalian and microbial manufacturing up to 2000L scale using disposable technology. Mycenax has 7 biosimilars in development and is evaluating opportunities for novel biologics. They aim to be a full service CDMO partner for biologics development and manufacturing.
High-throughput and Automated Process Development for Accelerated Biotherapeu...KBI Biopharma
KBI Biopharma has developed high-throughput and automated processes to accelerate biotherapeutic development. This includes establishing a high-throughput process development team utilizing automated equipment and informatics solutions. Analytical case studies demonstrate automation of a residual host cell protein ELISA using a liquid handling robot, reducing analysis time from hours to minutes per sample. A second case study outlines development of a high-throughput size exclusion chromatography method, reducing run time from 30 minutes to 6 minutes while still effectively screening for high molecular weight species. These efforts allow for real-time data generation and monitoring of process development experiments.
This document discusses strategies for orphan biopharmaceutical process development using contract development and manufacturing organizations (CDMOs). It notes that orphan biopharmaceuticals often require smaller scale and more flexible manufacturing. The document outlines considerations for clinical and commercial process development, including using single-use technologies, quality by design principles, and ensuring fidelity between clinical and commercial manufacturing processes. It emphasizes characterizing processes early and getting the process design right the first time for orphan drugs.
Integrity Bio is a protein formulation development, fill finish, and drug delivery CMO. Injectable formulations include protein,antibody, vaccine, and peptide. http://www.integritybio.com
High-throughput Miniaturized Bioreactors for Cell Culture Process Developmen...KBI Biopharma
Decreasing the timeframe for cell culture process development has been a key goal towards accelerating biopharmaceutical development. Automated Micro-scale Bioreactors (ambrTM) is an advanced micro bioreactor system with miniature single-use bioreactors with a 9-15mL working volume controlled by an automated workstation. This system was compared to conventional bioreactor systems in terms of its performance for the production of a monoclonal antibody and a non-antibody molecule in recombinant Chinese Hamster Ovary (CHO) cell lines.
The miniaturized bioreactor system was found to produce cell culture profiles that matched across scales to 3L, 15L and 200L stirred tank bioreactors. Moreover, changes to important process parameters in ambrTM resulted in predictable cell growth, viability and titer changes, which were in good agreement to historical data from the larger scales. ambrTM was found to successfully reproduce variations in temperature, dissolved oxygen and pH conditions similar to the larger bioreactor systems. Additionally, the miniature bioreactors were found to react well to perturbations in pH and dissolved oxygen through adjustments to the PID control loop. Overall, the studies demonstrate the utility of the ambrTM system as a high throughput system for cell culture process development.
Speed to GMP: Moving from Rapid Process Development to High Throughput Tech T...KBI Biopharma
This document discusses strategies for rapidly transferring biologics manufacturing processes from development to commercial production. It provides examples of how KBI Biopharma employs standardized platform processes and integrated development approaches to minimize changes between scales. For antibody processes, extensive use of platform cell lines, media, and unit operations allows seamless transfer. Non-antibody processes require more customization but subsequent products can still leverage a base platform. Tech transfer timelines are established early and deliverables like batch records are reviewed. This enables timely preparation for cGMP manufacturing and regulatory filings.
Presentation at BPI West by Abhinav A. Shukla, Ph.D. Senior Vice President Development & Manufacturing KBI Biopharma, Durham NC, February 27 – March 2, 2017, Platforms for mAb Commercialization
Quality by Design at a Biopharma CMO (Contract Manufacturing Organization)KBI Biopharma
A presentation by Abhinav A. Shukla, Ph.D., KBI's Vice President of Process Development & Manufacturing delivered at the ACC/QbD Conference (Society for Biological Engineering, AIChE), Coronado Island, CA, 2013.
Mycenax is a CDMO located in Taiwan that provides services for biologics development from cell line development through fill/finish. They have expertise in mammalian and microbial manufacturing up to 2000L scale using disposable technology. Mycenax has 7 biosimilars in development and is evaluating opportunities for novel biologics. They aim to be a full service CDMO partner for biologics development and manufacturing.
High-throughput and Automated Process Development for Accelerated Biotherapeu...KBI Biopharma
KBI Biopharma has developed high-throughput and automated processes to accelerate biotherapeutic development. This includes establishing a high-throughput process development team utilizing automated equipment and informatics solutions. Analytical case studies demonstrate automation of a residual host cell protein ELISA using a liquid handling robot, reducing analysis time from hours to minutes per sample. A second case study outlines development of a high-throughput size exclusion chromatography method, reducing run time from 30 minutes to 6 minutes while still effectively screening for high molecular weight species. These efforts allow for real-time data generation and monitoring of process development experiments.
This document discusses strategies for orphan biopharmaceutical process development using contract development and manufacturing organizations (CDMOs). It notes that orphan biopharmaceuticals often require smaller scale and more flexible manufacturing. The document outlines considerations for clinical and commercial process development, including using single-use technologies, quality by design principles, and ensuring fidelity between clinical and commercial manufacturing processes. It emphasizes characterizing processes early and getting the process design right the first time for orphan drugs.
Covering a Spectrum of New Product Development Technologies - From Cells to C...KBI Biopharma
KBI Biopharma provides analytical services, process development, and manufacturing for biologics from early discovery through commercialization. It has locations in Durham, Boulder, RTP, and The Woodlands focused on mammalian and microbial development as well as cell therapy. KBI leverages platform approaches for monoclonal antibodies, bispecific antibodies, fusion proteins, and emerging modalities. It has also partnered with Selexis to utilize their cell lines for development programs and has integrated Selexis cell lines into its platforms to rapidly develop cell lines from DNA to drug substance within 9 months.
Platform Techniques for Preformulation Development for Non-Antibody ProductsKBI Biopharma
A presentation from the IBC Non-Antibody Protein Therapeutics Development and Production Conference by KBI's Tim Kelly, Ph.D., Vice President, Biopharmaceutical Development.
Accelerated Stability During Formulation Development of Early Stage Protein T...KBI Biopharma
2008 IBC Formulation Strategies for Protein Therapeutics, Accelerated Stability During Formulation Development of Early Stage Protein Therapeutics – Pros and Cons of Contrasting Approaches. Vice President, Biopharmaceutical Development
Tim Kelly, Ph.D. KBI Biopharma, Inc.
Optimization of Glycosyation & Charge Distribution Through Culture Parameters...KBI Biopharma
This document summarizes three case studies conducted by Kinetic Biosciences Inc. regarding process optimization. Case Study 1 describes using a PAT approach involving daily charge variant testing to determine the optimal harvest day in three cGMP runs. Case Study 2 demonstrates how supplements can be used to customize product quality attributes like glycosylation. Case Study 3 shows that adding copper to the culture improved viability, titer and reproducibility that had been inconsistent due to variable pH changes after feeding. The document emphasizes the importance of analytics and surrogate markers in process development.
High Throughput Bioreactor Mimetic in Early and Late Stage Process DevelopmentKBI Biopharma
A presentation by KBI Scientist Shahid Rameez, Ph.D. at the American Chemical Society Annual Meeting– Biochemical Technology (BIOT) Division, New Orleans, LA
From Screening to QC: Development Considerations for Octet MethodsKBI Biopharma
- The document discusses the development of potency assays using the Octet platform for biotherapeutics.
- Case studies are presented showing potency assays can be developed in 5-6 days using Octet compared to 5-7 days using other technologies like ELISA or SPR.
- Assays developed on Octet show good accuracy, precision, specificity, linearity and range meeting regulatory guidelines.
- Potency assays have been used to support process development and manufacturing through to quality control.
Getting Biopharmaceutical Production Processes Right the First TimeKBI Biopharma
Strategies for rapid acceleration of cell line, upstream and downstream process development. A presentation by Ying Huang, Ph.D., Associate Director of Cell Line Development at KBI Biopharma. Presented at World Orphan Drug Congress. Washington DC. (2014)
Nextar ChemPharma Solutions provides integrated contract drug development and manufacturing services. They have over 35 experienced employees working in state-of-the-art laboratories and clean rooms. Their services include custom synthesis, formulation development, analytical testing, and GMP manufacturing of clinical trial materials. Nextar has successfully completed over 650 projects for 150 customers, developing over 50 innovative formulations and manufacturing over 25 products for clinical trials.
Significant advances in analytical technology over the past few years have improved the quantification and characterization capabilities for subvisible ( 1 - 100 μm) and submicron particles (≤1 μm). As the technology continues to improve so do the expectations of regulatory agencies for sponsors to characterize particles in these size ranges. However, multiple orthogonal methods are required to span the entire range and accurately characterize the particle profile. Each instrument has its own limitations based on detection method and properties of therapeutic protein products that must be well understood to generate high-quality data. Written by Amber Fradkin, Ph.D. Associate Director, R&D, KBI Biopharma
Data Collection on the ProteinSimple Maurice: Driving Compliance with the Emp...KBI Biopharma
This document discusses using the ProteinSimple Maurice system with Empower control software for analyzing proteins. It provides an overview of KBI Biopharma's analytical services and locations. It then describes the Maurice system and Empower software, highlighting how the software can be used to analyze charge heterogeneity, pI, purity and size of proteins from Maurice runs. It also notes some calculations that may need to be done in Excel if the Empower software does not automatically provide certain analysis values.
Next Generation Recombinant Protein ManufacturingKBI Biopharma
Next Generation Processes: What Model Works Best to Manufacture Recombinant Proteins in Asia?
BioPharma Asia 2017
Suntec Convention Center. Singapore, March 22, 2017
Thomas Jung, M.S. Vice President, Business Development
KBI Biopharma Inc.
Watch the presentation of this webinar here: https://bit.ly/3ELoVzo
Understanding how your mAb behaves under various conditions is a crucial part of product characterization and quality assurance programs. Join this panel-style webinar to gain insights into key aspects of stability testing, from regulatory expectations to timeline and design considerations.
To ensure product safety and enhance understanding of product attributes, careful study of the effects of environmental conditions on your mAb is required throughout all phases of development.
Long and short-term stability studies are a critical part of a product development program and required by ICH guidelines. However, stability programs require extensive preparation and without this proper planning you may face additional hurdles.
Join our experts, Drs. Greg Pirozzi and Pamela Hamill, in a panel style discussion to learn how to proactively plan and execute a testing program to assess changes in stability that may impact product purity, potency and safety.
In this webinar, you will learn:
• Key considerations on when and how to effectively plan your stability testing program
• How to ensure the right selection of assays for your testing package
• How forced degradation/accelerated studies may fit into your overall plan, and evaluating repeat stability requirements after CMC changes
Presented by:
Greg Pirozzi, Ph.D.
Senior Project Manager, Custom Projects
Pamela Hamill, Ph.D.
Technical Consultant, Field Technology Management
Debottlenecking Manufacturing Capacity Using High Seed Density Production Pro...KBI Biopharma
- Next-generation cell culture processes aim to reduce manufacturing timelines from 4-6 weeks to as little as 10 days while maintaining product quality and titers. This is done through high seed density production processes.
- A study demonstrated reducing a CHO cell culture process from 14-15 days to 10 days using a high seeding density, optimized media and feeds to support higher peak cell densities earlier. Process parameters were refined to scale this technique up successfully.
- Using high seed density production processes can increase facility utilization by 14-27% by reducing cell culture duration by 2-3 days. This approach offers more flexibility for scheduling manufacturing campaigns.
Oxidation of a Glycosylated Therapeutic ProteinKBI Biopharma
A presentation by Jimmy Smedley, Ph.D., (KBI Group Leader, Biopharmaceutical Development) from the Formulation Strategies for Protein Therapeutics Conference.
Scalability of a Single-Use Bioreactor Platform for Biopharmaceutical Manufac...KBI Biopharma
Presented at PepTalk 2017: San Diego, CA
Niket Bubna, Principal Scientist, Process Development, KBI Biopharma
Single-use Technologies And Continuous Processing
(Advancing Bioprocessing Through Technological Innovation)
Risk Mitigation Strategies For Single-use Technologies
Xpress Biologics provides protein and DNA manufacturing services to enable projects to transition from research to clinical trials. Their services include developing research cell banks, optimizing production and purification processes, and manufacturing research, GLP and GMP grade proteins and DNA in quantities ranging from 100 mg to 100 g. Their goal is to be a one-stop-shop for biologics manufacturing needs from early research through clinical trials.
Integration of Cell Line and Process Development to Expedite Delivery of Bisp...KBI Biopharma
This document summarizes the Selexis-KBI Integrated (SKI) workflow for expediting the development and delivery of bispecific antibodies to the clinic. The SKI workflow integrates cell line development, process development, and clinical manufacturing. Key aspects include:
- Using stable pools of clones early in development to assess product quality and titer with a platform process designed for bispecifics.
- Completing the first clinical manufacturing batch within 12 months by performing clone selection and process development in parallel.
- Demonstrating success with over 10 bispecific molecules, including increasing titer over 2-fold in one case and reducing homodimer levels by over 85% in another.
-
This document is a resume for Esam Abdelgadir. It summarizes his career objective to obtain a leadership role in biotechnology manufacturing or process development. It then outlines his 17 years of experience in cell culture process development and manufacturing roles at various biotech companies, including optimizing cell culture processes, supervising researchers, implementing changes to processes and facilities, and training and mentoring associates. His experience includes work with bioreactors from lab scale to 1000L, disposable technologies, analytics, and validation.
DCN Diagnostics offers OEM development services for complete lateral flow diagnostic systems. They have expertise in assay development, product engineering, manufacturing process development and commercialization assistance. Their services include reagent development, assay design, reader integration, design of plastic cassettes and cartridges, and manufacturing transfer. DCN has experience across various industries like medical diagnostics, veterinary, food testing, and can develop qualitative or quantitative lateral flow assays.
Covering a Spectrum of New Product Development Technologies - From Cells to C...KBI Biopharma
KBI Biopharma provides analytical services, process development, and manufacturing for biologics from early discovery through commercialization. It has locations in Durham, Boulder, RTP, and The Woodlands focused on mammalian and microbial development as well as cell therapy. KBI leverages platform approaches for monoclonal antibodies, bispecific antibodies, fusion proteins, and emerging modalities. It has also partnered with Selexis to utilize their cell lines for development programs and has integrated Selexis cell lines into its platforms to rapidly develop cell lines from DNA to drug substance within 9 months.
Platform Techniques for Preformulation Development for Non-Antibody ProductsKBI Biopharma
A presentation from the IBC Non-Antibody Protein Therapeutics Development and Production Conference by KBI's Tim Kelly, Ph.D., Vice President, Biopharmaceutical Development.
Accelerated Stability During Formulation Development of Early Stage Protein T...KBI Biopharma
2008 IBC Formulation Strategies for Protein Therapeutics, Accelerated Stability During Formulation Development of Early Stage Protein Therapeutics – Pros and Cons of Contrasting Approaches. Vice President, Biopharmaceutical Development
Tim Kelly, Ph.D. KBI Biopharma, Inc.
Optimization of Glycosyation & Charge Distribution Through Culture Parameters...KBI Biopharma
This document summarizes three case studies conducted by Kinetic Biosciences Inc. regarding process optimization. Case Study 1 describes using a PAT approach involving daily charge variant testing to determine the optimal harvest day in three cGMP runs. Case Study 2 demonstrates how supplements can be used to customize product quality attributes like glycosylation. Case Study 3 shows that adding copper to the culture improved viability, titer and reproducibility that had been inconsistent due to variable pH changes after feeding. The document emphasizes the importance of analytics and surrogate markers in process development.
High Throughput Bioreactor Mimetic in Early and Late Stage Process DevelopmentKBI Biopharma
A presentation by KBI Scientist Shahid Rameez, Ph.D. at the American Chemical Society Annual Meeting– Biochemical Technology (BIOT) Division, New Orleans, LA
From Screening to QC: Development Considerations for Octet MethodsKBI Biopharma
- The document discusses the development of potency assays using the Octet platform for biotherapeutics.
- Case studies are presented showing potency assays can be developed in 5-6 days using Octet compared to 5-7 days using other technologies like ELISA or SPR.
- Assays developed on Octet show good accuracy, precision, specificity, linearity and range meeting regulatory guidelines.
- Potency assays have been used to support process development and manufacturing through to quality control.
Getting Biopharmaceutical Production Processes Right the First TimeKBI Biopharma
Strategies for rapid acceleration of cell line, upstream and downstream process development. A presentation by Ying Huang, Ph.D., Associate Director of Cell Line Development at KBI Biopharma. Presented at World Orphan Drug Congress. Washington DC. (2014)
Nextar ChemPharma Solutions provides integrated contract drug development and manufacturing services. They have over 35 experienced employees working in state-of-the-art laboratories and clean rooms. Their services include custom synthesis, formulation development, analytical testing, and GMP manufacturing of clinical trial materials. Nextar has successfully completed over 650 projects for 150 customers, developing over 50 innovative formulations and manufacturing over 25 products for clinical trials.
Significant advances in analytical technology over the past few years have improved the quantification and characterization capabilities for subvisible ( 1 - 100 μm) and submicron particles (≤1 μm). As the technology continues to improve so do the expectations of regulatory agencies for sponsors to characterize particles in these size ranges. However, multiple orthogonal methods are required to span the entire range and accurately characterize the particle profile. Each instrument has its own limitations based on detection method and properties of therapeutic protein products that must be well understood to generate high-quality data. Written by Amber Fradkin, Ph.D. Associate Director, R&D, KBI Biopharma
Data Collection on the ProteinSimple Maurice: Driving Compliance with the Emp...KBI Biopharma
This document discusses using the ProteinSimple Maurice system with Empower control software for analyzing proteins. It provides an overview of KBI Biopharma's analytical services and locations. It then describes the Maurice system and Empower software, highlighting how the software can be used to analyze charge heterogeneity, pI, purity and size of proteins from Maurice runs. It also notes some calculations that may need to be done in Excel if the Empower software does not automatically provide certain analysis values.
Next Generation Recombinant Protein ManufacturingKBI Biopharma
Next Generation Processes: What Model Works Best to Manufacture Recombinant Proteins in Asia?
BioPharma Asia 2017
Suntec Convention Center. Singapore, March 22, 2017
Thomas Jung, M.S. Vice President, Business Development
KBI Biopharma Inc.
Watch the presentation of this webinar here: https://bit.ly/3ELoVzo
Understanding how your mAb behaves under various conditions is a crucial part of product characterization and quality assurance programs. Join this panel-style webinar to gain insights into key aspects of stability testing, from regulatory expectations to timeline and design considerations.
To ensure product safety and enhance understanding of product attributes, careful study of the effects of environmental conditions on your mAb is required throughout all phases of development.
Long and short-term stability studies are a critical part of a product development program and required by ICH guidelines. However, stability programs require extensive preparation and without this proper planning you may face additional hurdles.
Join our experts, Drs. Greg Pirozzi and Pamela Hamill, in a panel style discussion to learn how to proactively plan and execute a testing program to assess changes in stability that may impact product purity, potency and safety.
In this webinar, you will learn:
• Key considerations on when and how to effectively plan your stability testing program
• How to ensure the right selection of assays for your testing package
• How forced degradation/accelerated studies may fit into your overall plan, and evaluating repeat stability requirements after CMC changes
Presented by:
Greg Pirozzi, Ph.D.
Senior Project Manager, Custom Projects
Pamela Hamill, Ph.D.
Technical Consultant, Field Technology Management
Debottlenecking Manufacturing Capacity Using High Seed Density Production Pro...KBI Biopharma
- Next-generation cell culture processes aim to reduce manufacturing timelines from 4-6 weeks to as little as 10 days while maintaining product quality and titers. This is done through high seed density production processes.
- A study demonstrated reducing a CHO cell culture process from 14-15 days to 10 days using a high seeding density, optimized media and feeds to support higher peak cell densities earlier. Process parameters were refined to scale this technique up successfully.
- Using high seed density production processes can increase facility utilization by 14-27% by reducing cell culture duration by 2-3 days. This approach offers more flexibility for scheduling manufacturing campaigns.
Oxidation of a Glycosylated Therapeutic ProteinKBI Biopharma
A presentation by Jimmy Smedley, Ph.D., (KBI Group Leader, Biopharmaceutical Development) from the Formulation Strategies for Protein Therapeutics Conference.
Scalability of a Single-Use Bioreactor Platform for Biopharmaceutical Manufac...KBI Biopharma
Presented at PepTalk 2017: San Diego, CA
Niket Bubna, Principal Scientist, Process Development, KBI Biopharma
Single-use Technologies And Continuous Processing
(Advancing Bioprocessing Through Technological Innovation)
Risk Mitigation Strategies For Single-use Technologies
Xpress Biologics provides protein and DNA manufacturing services to enable projects to transition from research to clinical trials. Their services include developing research cell banks, optimizing production and purification processes, and manufacturing research, GLP and GMP grade proteins and DNA in quantities ranging from 100 mg to 100 g. Their goal is to be a one-stop-shop for biologics manufacturing needs from early research through clinical trials.
Integration of Cell Line and Process Development to Expedite Delivery of Bisp...KBI Biopharma
This document summarizes the Selexis-KBI Integrated (SKI) workflow for expediting the development and delivery of bispecific antibodies to the clinic. The SKI workflow integrates cell line development, process development, and clinical manufacturing. Key aspects include:
- Using stable pools of clones early in development to assess product quality and titer with a platform process designed for bispecifics.
- Completing the first clinical manufacturing batch within 12 months by performing clone selection and process development in parallel.
- Demonstrating success with over 10 bispecific molecules, including increasing titer over 2-fold in one case and reducing homodimer levels by over 85% in another.
-
This document is a resume for Esam Abdelgadir. It summarizes his career objective to obtain a leadership role in biotechnology manufacturing or process development. It then outlines his 17 years of experience in cell culture process development and manufacturing roles at various biotech companies, including optimizing cell culture processes, supervising researchers, implementing changes to processes and facilities, and training and mentoring associates. His experience includes work with bioreactors from lab scale to 1000L, disposable technologies, analytics, and validation.
DCN Diagnostics offers OEM development services for complete lateral flow diagnostic systems. They have expertise in assay development, product engineering, manufacturing process development and commercialization assistance. Their services include reagent development, assay design, reader integration, design of plastic cassettes and cartridges, and manufacturing transfer. DCN has experience across various industries like medical diagnostics, veterinary, food testing, and can develop qualitative or quantitative lateral flow assays.
Leslie M. Henson-Grochocki has over 15 years of experience in quality control and laboratory operations. She has worked at Amgen Inc. for over 11 years, holding several roles of increasing responsibility, where she developed and validated assays, implemented new inventory systems, and led process improvement projects. She has a demonstrated track record of applying Lean and Six Sigma methodologies to achieve efficiencies and has received multiple awards for her contributions.
Nandakumar Narayanan Kutty is a highly qualified microbiologist currently pursuing an MBA. He has experience in quality control and marketing for healthcare companies in Abu Dhabi and Bengaluru. He holds a Six Sigma Green Belt certification and has implemented lean six sigma initiatives to improve productivity. Kutty is seeking a position in healthcare quality or marketing where he can apply his expertise in auditing, quality control, and driving business growth.
DCN Diagnostics. Design and Development of Lateral Flow Assay SystemsBrendan O'Farrell
DCN Diagnostics designs and develops rapid assay systems for medical and veterinary diagnostics, bio-defense, agriculture, environmental testing and other market segments. DCN's service offering includes contract assay development, education and training courses in lateral flow technologies, industrial design and mechanical engineering services related to development of related devices for rapid diagnostics. Our specialties include lateral flow, flow through and microfluidic assay formats, and we have developed qualitative, quantitative, visual or fluorescent assay systems. DCN's ISO 9001:228 and EN 13485 compliant quality system is set up to allow us to deliver the full FDA compliant design history file. Our process and unique teams of highly experienced development scientists working alongside our engineering teams allow us to deliver the product, not just the parts. DCN Diagnostics is the sole supplier of cellulose nanobead technology for lateral flow diagnostics outside of Japan and can supply technical consulting and development assistance to companies wishing to develop and manufacture highly sensitive and quantitative lateral flow assays using the NanoAct (tm) beads. Our experience in multiplexing and joint ownership in the Symbolics patents covering aspects of multipex arraying in lateral flow formats allows DCN to assist our clients in creating highly unique and functional assays for any environment or application. DCN also provides our unique UltraGold (tm) colloidal gold for use in lateral flow assays. DCN's 40nm gold colloid is highly controlled, very stable and designed specifically for use in lateral flow and flow through assays.
Cellca provides cell line development services using its proprietary CHO expression platform to generate high producing cell lines from DNA to RCB within 4-5 months, with a track record of over 40 projects and 95% of cell lines producing over 3g/L of target protein; their scalable platform and optimized media system allows for robust process transfer from lab scale to production scale bioreactors up to 1000L.
Biodextris specializes in providing analytical development, process development, and quality control testing services for vaccines and biologics in clinical development. Comprised of experienced scientists located in Laval, Quebec, the group has worked together since 2002 developing numerous vaccine and biologic products. They offer a range of analytical, biophysical, physiochemical, immunological, and microbial characterization assays to support product development. Biodextris also provides process development, formulation, biomanufacturing, technology transfer, project management, and regulatory consulting services.
LakePharma is a contract research organization specializing in antibody and protein engineering, production, and cell line development. It offers a wide range of services including gene synthesis, cloning, DNA sequencing, plasmid production, immunizations, phage display, hybridoma development, cell line development, protein expression, purification, conjugation, characterization, assay development, and screening. LakePharma has dedicated teams, state-of-the-art facilities in the US, and proprietary technologies for antibody discovery, engineering, production, analytics, and assay development.
Ricerca Biosciences is a contract development and manufacturing organization located near Cleveland, Ohio on a 43-acre site. It has facilities for process research and development, analytical testing, and cGMP manufacturing. Ricerca has over 300 employees with extensive experience in chemical development. It provides services from drug discovery through commercial manufacturing, with a focus on developing robust, practical processes and ensuring a continuous supply of API. The document describes Ricerca's capabilities and facilities and provides an example project where it improved an early stage process, reducing costs and increasing supply for clinical trials.
The document provides a summary of Samha Lacoul's qualifications for a position as a laboratory technician or scientist. It outlines their technical skills and experience in areas such as HPLC, cell culture, quality control/assurance, and using various laboratory equipment and software programs. It also lists their education credentials and over 4 years of professional experience in quality control roles at pharmaceutical companies performing analytical testing and ensuring compliance with regulations.
Creative Enzymes uses its expertise in enzyme manufacturing to supply customers enzymes using for life science research and production of medicines, food, alcohol, beer, fruit juice, fabric, paper, leather goods, etc.
Janet Willis has over 10 years of experience in analytical chemistry and quality assurance. She holds a B.S. in Chemistry from UC San Diego and has worked at various pharmaceutical companies performing analytical testing, method development and validation, quality control, and quality assurance activities. Her experience includes HPLC, GC, UV-Vis, ELISA testing and method troubleshooting. She is proficient in GLP, GCP, and cGMP regulations and analytical software programs.
Praveen Kumar Galla has over 10 years of experience in the biopharmaceutical industry, having worked at companies like Biocon, Wockhardt, and Syngene. He currently works as an R&D Manager at GeneSys Biologics, leading a team that is setting up a laboratory for microbial expression. Praveen has expertise in upstream and downstream processing, process development, equipment operation, and cGMP compliance. He aims to take on new challenges and help the Indian biopharma industry through roles in middle management.
Cellca is a leading provider of Cell Line Development Services allowing customers easy open access to a cost effective reliable technology platform consistently delivering well characterised stable research clones from DNA to Research Cell Bank (RCB) in 4 months with titres upwards of 3.0 g/L in an easily scalable fed batch process.
The document is a resume for Kanagasabapathi S., highlighting his expertise and 10+ years of experience in bioanalytical method development and drug discovery. It summarizes his responsibilities developing over 1000 analytical methods for small molecules, conducting ADME assays, and managing projects. Currently he works as a Research Scientist at Syngene International Ltd, where he leads projects and trains junior scientists.
Adherent Lentivirus Suspension Production & Manufacturing.pptxGenScript ProBio
GenScript ProBio is the world's leading biotech company founded in 2002 in New Jersey USA. We at GenScript ProBio provide various solutions based on gene synthesis technology including lentivirus manufacturing, CAR-T IND filing, plasmid manufacturing & production, and many more.
Charles Henderson has over 10 years of experience in manufacturing technical support roles for pharmaceutical companies. He has extensive expertise in areas such as manufacturing operations, quality assurance, compliance, process improvement, and project management. Currently he works as a Manufacturing Technical Support Specialist at Roche Carolina, where he provides technical support for API manufacturing and leads projects involving qualification, technology transfer, and compliance.
Alan Cormier has over 10 years of experience in medical and biotechnology manufacturing. He has a strong background in quality control, production processes, and FDA compliance. He is skilled in process development, purification systems, equipment operation and maintenance, and training technicians. Cormier seeks a leadership position where he can utilize his expertise in cGMP manufacturing.
Kabe Lantry has over 10 years of experience working in laboratory services and biotechnology. Their experience includes laboratory hygiene, aseptic technique, quality control, inventory management, and equipment operation. They currently work as a Laboratory Services Technician at Amgen where they help ensure GMP compliance and minimize delays.
Gwendolyn Beagle has over 37 years of experience in chemical manufacturing, including roles in quality assurance, quality control, and production operations. She is currently the Quality Assurance/Quality Control Supervisor at Great Lakes Chemical, where she manages the quality control lab and ensures compliance with ISO and regulatory standards. Throughout her career, she has facilitated numerous continuous improvement initiatives focusing on safety, quality, and cost reductions.
Profiles of Iconic Fashion Personalities.pdfTTop Threads
The fashion industry is dynamic and ever-changing, continuously sculpted by trailblazing visionaries who challenge norms and redefine beauty. This document delves into the profiles of some of the most iconic fashion personalities whose impact has left a lasting impression on the industry. From timeless designers to modern-day influencers, each individual has uniquely woven their thread into the rich fabric of fashion history, contributing to its ongoing evolution.
Discover innovative uses of Revit in urban planning and design, enhancing city landscapes with advanced architectural solutions. Understand how architectural firms are using Revit to transform how processes and outcomes within urban planning and design fields look. They are supplementing work and putting in value through speed and imagination that the architects and planners are placing into composing progressive urban areas that are not only colorful but also pragmatic.
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...BBPMedia1
Nathalie zal delen hoe DEI en ESG een fundamentele rol kunnen spelen in je merkstrategie en je de juiste aansluiting kan creëren met je doelgroep. Door middel van voorbeelden en simpele handvatten toont ze hoe dit in jouw organisatie toegepast kan worden.
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.AnnySerafinaLove
This letter, written by Kellen Harkins, Course Director at Full Sail University, commends Anny Love's exemplary performance in the Video Sharing Platforms class. It highlights her dedication, willingness to challenge herself, and exceptional skills in production, editing, and marketing across various video platforms like YouTube, TikTok, and Instagram.
IMPACT Silver is a pure silver zinc producer with over $260 million in revenue since 2008 and a large 100% owned 210km Mexico land package - 2024 catalysts includes new 14% grade zinc Plomosas mine and 20,000m of fully funded exploration drilling.
4 Benefits of Partnering with an OnlyFans Agency for Content Creators.pdfonlyfansmanagedau
In the competitive world of content creation, standing out and maximising revenue on platforms like OnlyFans can be challenging. This is where partnering with an OnlyFans agency can make a significant difference. Here are five key benefits for content creators considering this option:
𝐔𝐧𝐯𝐞𝐢𝐥 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐄𝐧𝐞𝐫𝐠𝐲 𝐄𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 𝐰𝐢𝐭𝐡 𝐍𝐄𝐖𝐍𝐓𝐈𝐃𝐄’𝐬 𝐋𝐚𝐭𝐞𝐬𝐭 𝐎𝐟𝐟𝐞𝐫𝐢𝐧𝐠𝐬
Explore the details in our newly released product manual, which showcases NEWNTIDE's advanced heat pump technologies. Delve into our energy-efficient and eco-friendly solutions tailored for diverse global markets.
Best Competitive Marble Pricing in Dubai - ☎ 9928909666Stone Art Hub
Stone Art Hub offers the best competitive Marble Pricing in Dubai, ensuring affordability without compromising quality. With a wide range of exquisite marble options to choose from, you can enhance your spaces with elegance and sophistication. For inquiries or orders, contact us at ☎ 9928909666. Experience luxury at unbeatable prices.
[To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
This PowerPoint compilation offers a comprehensive overview of 20 leading innovation management frameworks and methodologies, selected for their broad applicability across various industries and organizational contexts. These frameworks are valuable resources for a wide range of users, including business professionals, educators, and consultants.
Each framework is presented with visually engaging diagrams and templates, ensuring the content is both informative and appealing. While this compilation is thorough, please note that the slides are intended as supplementary resources and may not be sufficient for standalone instructional purposes.
This compilation is ideal for anyone looking to enhance their understanding of innovation management and drive meaningful change within their organization. Whether you aim to improve product development processes, enhance customer experiences, or drive digital transformation, these frameworks offer valuable insights and tools to help you achieve your goals.
INCLUDED FRAMEWORKS/MODELS:
1. Stanford’s Design Thinking
2. IDEO’s Human-Centered Design
3. Strategyzer’s Business Model Innovation
4. Lean Startup Methodology
5. Agile Innovation Framework
6. Doblin’s Ten Types of Innovation
7. McKinsey’s Three Horizons of Growth
8. Customer Journey Map
9. Christensen’s Disruptive Innovation Theory
10. Blue Ocean Strategy
11. Strategyn’s Jobs-To-Be-Done (JTBD) Framework with Job Map
12. Design Sprint Framework
13. The Double Diamond
14. Lean Six Sigma DMAIC
15. TRIZ Problem-Solving Framework
16. Edward de Bono’s Six Thinking Hats
17. Stage-Gate Model
18. Toyota’s Six Steps of Kaizen
19. Microsoft’s Digital Transformation Framework
20. Design for Six Sigma (DFSS)
To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women MagazineCIOWomenMagazine
In this article, we will dive into the extraordinary life of Ellen Burstyn, where the curtains rise on a story that's far more attractive than any script.
Industrial Tech SW: Category Renewal and CreationChristian Dahlen
Every industrial revolution has created a new set of categories and a new set of players.
Multiple new technologies have emerged, but Samsara and C3.ai are only two companies which have gone public so far.
Manufacturing startups constitute the largest pipeline share of unicorns and IPO candidates in the SF Bay Area, and software startups dominate in Germany.
Best practices for project execution and deliveryCLIVE MINCHIN
A select set of project management best practices to keep your project on-track, on-cost and aligned to scope. Many firms have don't have the necessary skills, diligence, methods and oversight of their projects; this leads to slippage, higher costs and longer timeframes. Often firms have a history of projects that simply failed to move the needle. These best practices will help your firm avoid these pitfalls but they require fortitude to apply.
Navigating the world of forex trading can be challenging, especially for beginners. To help you make an informed decision, we have comprehensively compared the best forex brokers in India for 2024. This article, reviewed by Top Forex Brokers Review, will cover featured award winners, the best forex brokers, featured offers, the best copy trading platforms, the best forex brokers for beginners, the best MetaTrader brokers, and recently updated reviews. We will focus on FP Markets, Black Bull, EightCap, IC Markets, and Octa.
SATTA MATKA SATTA FAST RESULT KALYAN TOP MATKA RESULT KALYAN SATTA MATKA FAST RESULT MILAN RATAN RAJDHANI MAIN BAZAR MATKA FAST TIPS RESULT MATKA CHART JODI CHART PANEL CHART FREE FIX GAME SATTAMATKA ! MATKA MOBI SATTA 143 spboss.in TOP NO1 RESULT FULL RATE MATKA ONLINE GAME PLAY BY APP SPBOSS
Digital Marketing with a Focus on Sustainabilitysssourabhsharma
Digital Marketing best practices including influencer marketing, content creators, and omnichannel marketing for Sustainable Brands at the Sustainable Cosmetics Summit 2024 in New York
1. 1/3
PROCESS &
FORMULATION
DEVELOPMENT
Kemwell provides extensive mammalian cell culture based products’ development services. The labs have the
capability of performing complete process development, process optimization, scale-up, technology-transfers and
process characterization. Moreover, our scientists have demonstrated the capability to design and execute
development work to meet defined product quality attributes. Kemwell’s integrated cross-functional project teams
comprise of process and analytical development scientists who work closely together leading to excellent product
and process understanding. Each customer project is individually customized to match the customer’s requirements
as per the scope.
Kemwell routinely provides the following development services:
• Upstream and Downstream process Development
• Analytical methods and formulation development (including lyophilized formulations)
• Clone screening and selection
• Cell line stability studies
• Media and cell culture optimization
• Optimizing mfg. processes to improve process time and increase yields/outputs
• Achieving efficient process scale-up
• Reducing of manufacturing costs and time – through process improvements
• Process characterization
• Establishment of scale-down models
• Univariate and multivariate DoE studies
• Studies to define critical and key process parameters, establishment of design space, etc.
• Control strategy
• Head to head comparability studies of biosimilars
• Development stability studies
• Preclinical manufacturing capabilities at 5L, 10L and 80L scale
PROCESS & FORMULATION DEVELOPMENT
2. UPSTREAM PROCESS DEVELOPMENT
Kemwell’s team of experienced scientists and analysts specialize in mammalian cell culture process development. We
use well versed techniques such as design-of-experiments approach for process optimization to reach optimal titer
values and generate superior quality products. We strive to develop a robust, efficient, scaled up manufacturing
process to deliver consistent product quality.
DOWNSTREAM PROCESS DEVELOPMENT
Kewell’s purification process development team develops robust, economical processes for mammalian cell culture
products. The design-of-experiments approach for process optimization and process characterization is used in order
to achieve optimal yields. Our foremost goal is product quality and we strive to generate superior quality products. A
close collaboration with analytical method development scientists ensures in-process testing scheme development.
Lab infrastructure
• Biosafety cabinets and Laminar Air Flow Units for
aseptic work
• Access controlled cell bank (research cell banks and
working cell banks) storage facility
• CO2 incubators for shake flask experiments
• Bioreactors
• 5L and 10L glass bioreactors
• 80L SS bioreactor
• WAVE bioreactor™
• ATF-2 perfusion
• CEDEX bioanalyzer
• Cell viability analyser
• AKTA purifier™
• AKTA pilot™
• Cogent TFF systems
• Milistak+Pod filtration system
PROCESS & FORMULATION DEVELOPMENT 2/3
3. CONTACT US
Bangalore, India
+91 80 2698 2400 www.kemwellbiopharma.com
3/3
FORMULATION DEVELOPMENT
Overview
Kemwell offers formulation development services for early and late stage clinical development and commercial
products based on target formulation profiles. Formulation development work is carried out collaboratively with
analytical development groups to ensure that robust and stability indicating analytical methods are used appropriately
during formulation development. Accelerated and real-time stability studies, and varieties of stress stability are
employed to deliver the best formulation for your product.
Preformulation Studies
• Evaluation of biophysical characteristics
• Assessment of ‘thermodynamic stability’
• Identification of critical factors that impact stability
Formulation Screening Studies
• Formulation screening studies to select optimal formulation for the molecule
• Integrated formulation and analytical method development team to ensure right methods are available for
evaluating degradation routes of molecule to enable formulation screening studies
Lyophilization Cycle Development
• Lyophilization cycle development for molecules that may have inherently lower stability in liquid form
• Optimization of each phase of the cycle to ensure an efficient, robust and scalable process
PROCESS & FORMULATION DEVELOPMENT